Drug reference
nadroparin
Low molecular weight heparin · Anticoagulant
Low molecular weight heparinAnticoagulant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
Prophylaxis of deep vein thrombosisProphylaxis of pulmonary embolism (in high-risk patients undergoing surgery; stroke or other immobilized patients)Treatment of established deep vein thrombosisUnstable anginaMyocardial infarctionMaintain patency of cannulae and shunts in dialysis patients
Dosing
- Adult
- 3075 IU (0.3 ml) and 4100 IU (0.4 ml) inj. CARDIOPARIN 4000 anti Xa IU/0.4 ml, 6000 anti Xa IU/0.6 ml, 100,000 anti Xa IU/10 ml inj.
Related guidelines
ST-elevation myocardial infarction
CSI · Cardiology · 2020
Venous thromboembolism prophylaxis
ASH · Haematology · 2018
Acute coronary syndrome
CSI · Cardiology · 2022
Preoperative cardiac evaluation for non-cardiac surgery
AHA · Cardiology · 2025
Dialysis — initiation and maintenance
ISN_INDIA · Nephrology · 2023
Other Low molecular weight heparin drugs
Ask House about nadroparin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team